| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
NVCR
NovoCure
|
Jun 22, 2026 | BUY |
Strong Buy
+233.6% avg upside
11 analysts
|
$46.00
212.49% Upside
|
· |
|
COAG
Hemab Therapeutics Holdings, Inc.
|
Jun 17, 2026 | BUY |
Strong Buy
+43.9% avg upside
5 analysts
|
$40.00
39.12% Upside
|
· |
|
AGIO
Agios Pharma
|
Jun 15, 2026 | BUY |
Strong Buy
+63.5% avg upside
29 analysts
|
$54.00
48.80% Upside
|
· |
|
CNTX
Context Therapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+939.9% avg upside
12 analysts
|
$5.00
768.11% Upside
|
· |
|
SABS
SAB Biotherapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+176.3% avg upside
14 analysts
|
$10.00
160.45% Upside
|
· |
|
ATOS
Atossa Therapeutics
|
Jun 15, 2026 | HOLD |
Strong Buy
+999.8% avg upside
6 analysts
|
— | · |
|
TGTX
TG Therapeutics
|
Jun 09, 2026 | BUY |
Strong Buy
-30.3% avg upside
19 analysts
|
$70.00
30.50% Upside
|
+26.2% |
|
ARTV
Artiva Biotherapeutics, Inc.
|
Jun 08, 2026 | BUY |
Strong Buy
+253.0% avg upside
7 analysts
|
$35.00
275.52% Upside
|
+52.1% |
|
RCUS
Arcus Biosciences
|
Jun 03, 2026 | BUY |
Strong Buy
+17.6% avg upside
20 analysts
|
$32.00
11.13% Upside
|
+18.1% |
|
OLMA
Olema Pharmaceuticals
|
Jun 03, 2026 | BUY |
Strong Buy
+248.4% avg upside
16 analysts
|
$38.00
241.20% Upside
|
+6.0% |
|
VTVT
vTv Therapeutics
|
May 26, 2026 | BUY |
Strong Buy
-7.6% avg upside
12 analysts
|
$45.00
25.98% Upside
|
+1.8% |
|
AGEN
Agenus
|
May 22, 2026 | BUY |
Strong Buy
+170.2% avg upside
17 analysts
|
$23.00
687.76% Upside
|
· |
|
PPBT
Purple Biotech
|
May 18, 2026 | BUY |
Strong Buy
+2090.5% avg upside
4 analysts
|
$30.00
1614.37% Upside
|
-20.4% |
|
INKT
MiNK Therapeutics
|
May 15, 2026 | BUY |
Strong Buy
+81.7% avg upside
6 analysts
|
$35.00
188.98% Upside
|
+5.3% |
|
TRAX
First Tracks Biotherapeutics Inc
|
May 15, 2026 | BUY |
Strong Buy
+118.0% avg upside
7 analysts
|
$30.00
79.68% Upside
|
· |
|
SNTI
Senti Biosciences
|
May 15, 2026 | BUY |
Strong Buy
+720.6% avg upside
7 analysts
|
$12.00
1011.06% Upside
|
-5.9% |
|
ACRV
Acrivon Therapeutics, Inc.
|
May 14, 2026 | BUY |
Strong Buy
+782.5% avg upside
13 analysts
|
$19.00
1072.77% Upside
|
-7.8% |
|
NKTX
Nkarta
|
May 13, 2026 | BUY |
Strong Buy
+544.9% avg upside
16 analysts
|
$16.00
453.59% Upside
|
-13.7% |
|
AUTL
Autolus Therapeutics
|
May 13, 2026 | BUY |
Strong Buy
+566.6% avg upside
16 analysts
|
$10.00
528.96% Upside
|
-2.9% |
|
SANA
Sana Biotechnology
|
May 12, 2026 | BUY |
Strong Buy
+200.1% avg upside
14 analysts
|
$7.00
113.46% Upside
|
+2.8% |
|
GNLX
Genelux Corp.
|
May 08, 2026 | BUY |
Strong Buy
+528.6% avg upside
7 analysts
|
$31.00
987.63% Upside
|
-6.1% |
|
GERN
Geron
|
May 06, 2026 | HOLD |
Strong Buy
+209.8% avg upside
19 analysts
|
— | -9.5% |
|
IMNN
Imunon
|
Apr 02, 2026 | BUY |
Buy
+727.5% avg upside
11 analysts
|
$25.00
1345.10% Upside
|
-16.8% |
|
ANAB
AnaptysBio
|
Mar 30, 2026 | BUY |
Strong Buy
+23.3% avg upside
26 analysts
|
$66.00
12.83% Upside
|
+58.8% |
|
JSPR
Jasper Therapeutics
|
Mar 30, 2026 | BUY |
Strong Buy
+5846.4% avg upside
17 analysts
|
$20.00
3976.69% Upside
|
-47.7% |
|
VNDA
Vanda
|
Feb 23, 2026 | BUY |
Strong Buy
+246.6% avg upside
13 analysts
|
$18.00
205.15% Upside
|
-22.9% |
|
IOBTQ
IO Biotech
|
Nov 17, 2025 | HOLD |
Buy
+73209.5% avg upside
6 analysts
|
— | · |
|
NXTC
NextCure
|
Nov 17, 2025 | BUY |
Strong Buy
+887.1% avg upside
10 analysts
|
$20.00
1029.87% Upside
|
-4.0% |
|
TSE:BCT
BriaCell Therapeutics
|
Oct 13, 2025 | BUY |
Strong Buy
+1221.6% avg upside
1 analyst
|
$56.83
1221.63% Upside
|
· |
|
FEMY
Femasys
|
Sep 26, 2025 | BUY |
Strong Buy
+1473.5% avg upside
6 analysts
|
$160.00
4259.64% Upside
|
-43.9% |
|
RNAZ
TransCode Therapeutics
|
Apr 29, 2025 | HOLD |
Buy
+9706.0% avg upside
2 analysts
|
— | -20.0% |
|
CNTB
Connect Biopharma Holdings
|
Mar 31, 2025 | BUY |
Strong Buy
+208.5% avg upside
11 analysts
|
$8.00
277.39% Upside
|
+376.4% |
|
LTRN
Lantern Pharma
|
May 22, 2024 | HOLD |
Strong Buy
+469.0% avg upside
5 analysts
|
— | -48.1% |
|
SQZB
SQZ Biotechnologies
|
Jul 11, 2023 | HOLD |
Buy
+102677.7% avg upside
7 analysts
|
— | +0.0% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.